Public-Facing Data
COVID-19 Research
Bronx RHIO is working with a group of researchers at Montefiore and the Albert Einstein College of Medicine to perform an CDC-funded research study investigating factors related to the high rate of COVID-19 infection and disease severity in the Bronx, especially social determinants of health. In addition to member-generated research projects, the Bronx RHIO has begun preliminary internal analyses on COVID-19 risk factors, complications, and outcomes, which are intended to be made publicly available as de-identified analyses in the future.
Read about more our COVID-19 Alerts for our Participant Organizations.
COVID-19 Tracking Project (Completed)
Heat map of COVID-19 cases in the Bronx from March 2020 - February 2021. Click to expand.
Animated heat map of COVID-19 geospatial data from February through July 2020.
COVID-19 Reporting
When the COVID-19 outbreak began in New York, the Bronx RHIO quickly adapted our resources to serve public health agencies and our diverse membership. Bronx RHIO integrated the State-provided Electronic Clinical Lab Reporting System (ECLRS) data into our Virtual Health Record, including a prominent COVID-19 flag displayed along the top of the screen.
In addition to the ECLRS data, Bronx RHIO identified a range of clinical indicators of COVID-19 infection and related factors. As knowledge developed about COVID-19 treatments, risk factors, and complications, Bronx RHIO continuously worked to find clinical data elements to track these factors. Bronx RHIO also worked with its large data contributors to expand and refine the clinical data they provided, such as respiratory flow sheets, which included richer ventilation use data. By analyzing real-time member data, including labs, medications, observations, progress notes, diagnoses, and procedures, Bronx RHIO tracked and reported:
Confirmed COVID-19 infections and antibodies
Active COVID-19 infections and presumed recovered cases
COVID-19 test positivity rate
COVID-19 deaths in hospitals and nursing homes
Comorbidities, with special attention on lupus and HIV patients and the potential for their chronic disease management medications to provide protection from COVID-19
COVID-19 treatment medication use (e.g. remdesivir)
Social determinants: race, ethnicity, age, sex, housing status, neighborhood-level poverty data
Hospitalization and ICU use
Intubation, ventilator, and ECMO use
Stroke and Pediatric Multisystem Inflammatory Syndrome in COVID-19 patients
Smoking status and BMI
